Mode
Text Size
Log in / Sign up

Probiotics, synbiotics, and berberine modestly lower fasting glucose and HbA1c in type 2 diabetesProbiotics and Berberine Modestly Lower Blood Sugar in Type 2 Diabetes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider probiotics, synbiotics, and berberine as adjunctive options for modest glucose lowering in type 2 diabetes.

This systematic review and meta-analysis synthesized evidence from trials involving over 2,000 participants with type 2 diabetes mellitus. The authors evaluated the effects of probiotics, synbiotics, and berberine compared to placebo on fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c).

The meta-analysis found a pooled reduction in FPG of -0.71 mmol·L⁻¹ and a reduction in HbA1c of -0.19%. When considering probiotics alone, the effect sizes were approximately -0.80 mmol·L⁻¹ for FPG and approximately -0.21% for HbA1c. The authors describe these as significant but modest reductions.

Key limitations noted by the authors include substantial between-study variability and the need for larger and longer trials with standardized interventions. Safety data, including adverse events and discontinuations, were not reported in the included studies.

The authors conclude that these interventions may support their use as adjunctive, rather than primary, therapeutic options for type 2 diabetes. Practice relevance is framed cautiously, emphasizing the modest nature of the improvements and the need for further research.

A new analysis of multiple studies suggests that probiotics, synbiotics, and the supplement berberine can help lower blood sugar levels in people with type 2 diabetes. The review combined data from over 2,000 participants and found that these supplements led to small but significant reductions in fasting plasma glucose (by about 0.71 mmol/L) and glycated hemoglobin (HbA1c) by about 0.19%. When looking at probiotics alone, the reductions were similar: roughly 0.80 mmol/L for blood sugar and 0.21% for HbA1c.

These results are promising, but it is important to keep them in perspective. The improvements were modest, meaning they are not a replacement for standard diabetes treatments like medication, diet, and exercise. The researchers note that there was a lot of variation between the studies, which makes the findings less certain. They also call for larger and longer trials with standardized doses and types of supplements.

No serious safety concerns were reported in the studies, but the analysis did not detail side effects. The takeaway is that probiotics, synbiotics, and berberine might be helpful additions to a diabetes management plan, but they should not be used as a primary treatment. Always talk to your doctor before starting any new supplement.

What this means for you:
Probiotics and berberine may offer modest blood sugar benefits as add-ons, not replacements, for diabetes care.

Study Details

Study typeMeta analysis
Sample sizen = 2,000
EvidenceLevel 1
PublishedJan 2026
View Original Abstract ↓
BACKGROUND: Type 2 diabetes mellitus is characterized by impaired regulation of blood glucose. Probiotics, synbiotics, and berberine (BBR) have been proposed as adjunctive interventions, but their overall effectiveness remains uncertain. OBJECTIVE: To evaluate the effects of these interventions on glycemic control and to explore a potential molecular interaction of BBR with a key carbohydrate-digesting enzyme. METHODS: A systematic review and meta-analysis of randomized controlled trials was conducted. Pooled effects were estimated for fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) using random-effects models. A subgroup analysis compared probiotics with placebo. An exploratory computational analysis examined the interaction of BBR with α-glucosidase. RESULTS: More than 30 trials involving over 2,000 participants were included. The pooled analysis showed significant but modest reductions in FPG (-0.71 mmol·L ⁻ ¹) and HbA1c (-0.19%), with substantial between-study variability. Probiotics alone also reduced FPG (approximately -0.80 mmol·L ⁻ ¹) and HbA1c (approximately -0.21%) compared with placebo. Computational analysis indicated weaker enzyme binding for BBR than for the reference inhibitor acarbose. CONCLUSIONS: Probiotics, synbiotics, and BBR provide statistically significant but clinically modest improvements in glycemic control. These findings support their use as adjunctive, rather than primary, therapeutic options and highlight the need for larger and longer trials with standardized interventions. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251116387, identifier CRD420251116387.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.